Patients: 8323 patients ≥ 40 years of age (mean age 65 y, 63% men) who had been hospitalized in the past 48 hours for ≥ 1 of acute decompensation of heart failure, active cancer (excluding planned stays for chemotherapy), or severe systemic infection; had ≥ 1 of chronic pulmonary disease, body mass index ≥ 30, age ≥ 60 years, or history of venous thromboembolism (VTE); and had an expected stay ≥ 6 days and an American Society of Anesthesiologists health status score ≤ 3 out of 6 or an Eastern Cooperative Oncology Group performance status score ≤ 2 out of 5. Exclusion criteria included recent major surgery or trauma, recent stroke, severe renal failure, ventilator support with intubation, and active bleeding.
Intervention: Subcutaneous enoxaparin, 40 mg/d (n = 4174), or placebo (0.9% saline) (n = 4145), for 6 to 14 days. All patients wore knee-high, elastic, graduated compression stockings.
Outcomes: Primary efficacy outcome was all-cause mortality at 30 days. Other outcomes included major bleeding events, all-cause mortality at 90 days, and cardiopulmonary mortality (sudden death or death due to acute myocardial infarction, heart failure, or pulmonary embolism) at 30 and 90 days. The study had 77% power to detect a 25% reduction from the 4.8% observed 30-day mortality rate in the placebo group (2-sided α = 0.05).
Patient follow-up: 99% at 90 days (intention-to-treat analysis).

Main results
Enoxaparin and placebo did not differ for all-cause or cardiopulmonary mortality at 30 or 90 days (Table) ; groups also did not differ for major bleeding during or ≤ 14 days after treatment (n = 8307, 0.4% vs 0.3%, P = 0.35).
Conclusion
Thromboprophylaxis with enoxaparin did not reduce mortality or increase major bleeding events in acutely ill medical patients. 
*
Commentary
Medical professional societies and hospital accreditation bodies have accepted the false logic that since VTE is one of the most common causes of preventable death in the hospital, VTE prophylaxis in medical patients saves lives (1). The inclusion of asymptomatic deep venous thrombosis (DVT) as a surrogate outcome in thromboprophylaxis trials has led many to overestimate the efficacy of prophylaxis for preventing clinically important outcomes, which makes the risk for bleeding associated with these therapies seem minor in comparison. As a result, many health care systems have adopted policies that make pharmacologic VTE prophylaxis the "default" for medical inpatients. The findings of the LIFENOX study raise questions about such policies.
It is not surprising that this study did not show a mortality benefit of thromboprophylaxis with enoxaparin. Hospitalized medical patients have multiple comorbid conditions with risk for mortality far greater than that from VTE. Thus, we need to rethink promulgating mortality as the endpoint justifying thromboprophylaxis in medical inpatients. Some have suggested that the primary rationale for widespread pharmacologic prophylaxis should be reduction of symptomatic VTE. However, because the absolute risk for symptomatic VTE in medical inpatients is < 1%, a more nuanced approach to prescribing prophylaxis is warranted. Indeed, in LIFENOX-a study designed to enroll only patients at increased risk for VTEonly 0.1% of patients in the placebo group and 0.2% in the enoxaparin group had confirmed symptomatic VTE during 90 days of follow-up. In the absence of a prospectively validated risk prediction tool, it is difficult to know which patients will benefit from prophylaxis and which will have unnecessary bleeding. Although the results of the LIFENOX study indirectly suggest that elastic compression stockings may offer protection, the efficacy of stockings and pneumatic compression devices is not well-established in medical patients (2), and they are not currently recommended unless an excessive bleeding risk precludes prophylactic anticoagulation.
